NCT Number: NCT04868604
Phase: Phase 1|Phase 2
Trial Summary: The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant p – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Clarity Pharmaceuticals Ltd
Acronym: SECuRE
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives